Mark B. Mcclellan

Mark B. Mcclellan's AcademicInfluence.com Rankings

Mark B. Mcclellan

Economics

#3242

World Rank

#3677

Historical Rank

economics Degrees

Mark B. Mcclellan

Philosophy

#8218

World Rank

#11555

Historical Rank

Logic

#5251

World Rank

#6636

Historical Rank

philosophy Degrees

Download Badge

Economics
Philosophy

Mark B. Mcclellan's Degrees

Doctorate Medicine Harvard University

Why Is Mark B. Mcclellan Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Mark B. Mcclellan's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Is technological change in medicine worth it? (2001) (919)
Do Doctors Practice Defensive Medicine? (1996) (635)
Association of Renal Insufficiency with Treatment and Outcomes after Myocardial Infarction in Elderly Patients (2002) (598)
A national strategy to put accountable care into practice. (2010) (423)
Developing the Sentinel System--a national resource for evidence development. (2011) (326)
How does managed care do it? (2000) (292)
Fostering accountable health care: moving forward in medicare. (2009) (290)
Does More Intensive Treatment of Acute Myocardial Infarction in the Elderly Reduce Mortality? Analysis Using Instrumental Variables (1995) (289)
Are Medical Prices Declining? Evidence from Heart Attack Treatments (1998) (244)
Trends in inpatient treatment intensity among Medicare beneficiaries at the end of life. (2004) (213)
The new Sentinel Network--improving the evidence of medical-product safety. (2009) (208)
Trends in treatment and outcomes for acute myocardial infarction: 1975-1995. (2001) (183)
Mortality After Acute Myocardial Infarction in Hospitals That Disproportionately Treat Black Patients (2005) (179)
Cost-Effectiveness of Alternative Management Strategies for Patients with Solitary Pulmonary Nodules (2003) (179)
Managed care, hospice use, site of death, and medical expenditures in the last year of life. (2002) (170)
Medicare coverage of ICDs. (2005) (165)
AHRQ Quality Indicators Guide to Prevention Quality Indicators : Hospital Admission for Ambulatory Care Sensitive Conditions (2001) (156)
Hospital Reimbursement Incentives: An Empirical Analysis (1997) (149)
Comparative effectiveness research: Policy context, methods development and research infrastructure (2010) (148)
Vital Directions for Health and Health Care: Priorities From a National Academy of Medicine Initiative (2017) (148)
Using Digital Health Technology to Better Generate Evidence and Deliver Evidence-Based Care. (2018) (147)
How Liability Law Affects Medical Productivity (2000) (143)
The Incidence of Medicare (1997) (139)
The Quality of Health Care Providers (1999) (135)
Building the path to accountable care. (2011) (131)
The Determinants of Technological Change in Heart Attack Treatment (1996) (122)
Malpractice law and health care reform: optimal liability policy in an era of managed care (2002) (120)
The FDA Sentinel Initiative - An Evolving National Resource. (2018) (116)
Call to Action: Urgent Challenges in Cardiovascular Disease A Presidential Advisory From the American Heart Association (2019) (111)
Refinement of the HCUP Quality Indicators (2001) (104)
The marginal cost-effectiveness of medical technology: A panel instrumental-variables approach (1997) (102)
Reforming payments to healthcare providers: the key to slowing healthcare cost growth while improving quality? (2011) (102)
Implementing MACRA: Implications for Physicians and for Physician Leadership. (2016) (101)
National coronavirus response: A road map to reopening (2020) (95)
Unintended consequences of steps to cut readmissions and reform payment may threaten care of vulnerable older adults. (2012) (87)
Repairing the Broken Market for Antibiotic Innovation (2015) (85)
Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction. (2001) (82)
Ensuring safe and effective medical devices. (2003) (82)
Health Events, Health Insurance, and Labor Supply: Evidence from the Health and Retirement Survey (1998) (79)
Drug safety reform at the FDA--pendulum swing or systematic improvement? (2007) (78)
Are Medical Prices Declining? (1996) (76)
The Effects of Malpractice Pressure and Liability Reforms on Physicians' Perceptions of Medical Care (1998) (71)
Pricing Heart Attack Treatments (1999) (69)
Satisfaction guaranteed--"payment by results" for biologic agents. (2007) (69)
Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. (2000) (69)
The Costs and Benefits of Intensive Treatment for Cardiovascular Disease (1998) (67)
Detecting Medicare Abuse (2004) (67)
Ownership Form and Trapped Capital in the Hospital Industry (2002) (59)
Health reform and physician-led accountable care: the paradox of primary care physician leadership. (2014) (54)
Comparing the Quality of Health Care Providers (2000) (52)
Accountable care around the world: a framework to guide reform strategies. (2014) (50)
A global analysis of technological change in health care: the case of heart attacks. The TECH Investigators. (2018) (50)
Does physician specialty affect the survival of elderly patients with myocardial infarction? (2000) (49)
Productivity Change in Health Care (2001) (46)
Racial and sex differences in refusal of coronary angiography. (2002) (46)
Technological Change in Heart-Disease Treatment: Does High Tech Mean Low Value? (1998) (45)
The first months of the prescription-drug benefit--a CMS update. (2006) (43)
Medical Care at the End of Life: Diseases, Treatment Patterns, and Costs (1998) (41)
Beyond the Affordable Care Act: achieving real improvements in Americans' health. (2010) (41)
Insurance or Self-Insurance?: Variation, Persistence, and Individual Health Accounts (1996) (39)
Persistence of Medicare Expenditures among Elderly Beneficiaries (1997) (39)
Vital Directions for Health and Health Care: An Initiative of the National Academy of Medicine. (2016) (39)
The marginal benefits of invasive treatments for acute myocardial infarction: does insurance coverage matter? (2000) (37)
Bending the curve: effective steps to address long-term healthcare spending growth. (2009) (37)
Technological Change in Health Care: A Global Analysis of Heart Attack (2002) (36)
Utilization and outcomes of the implantable cardioverter defibrillator, 1987 to 1995. (2002) (35)
Effectiveness and cost-effectiveness of implantable cardioverter defibrillators in the treatment of ventricular arrhythmias among medicare beneficiaries. (2002) (35)
Uncertainty, health-care technologies, and health-care choices. (1995) (34)
Effectiveness and cost-effectiveness of implantable cardioverter defibrillators in the treatment of ventricular arrhythmias among medicare beneficiaries (2002) (33)
Comparing Associations of State Reopening Strategies with COVID-19 Burden (2020) (33)
What Has Increased Medical-Care Spending Bought? (1998) (33)
Early experiences with accountable care in Medicaid: special challenges, big opportunities. (2013) (32)
An evaluation of recent federal spending on comparative effectiveness research: priorities, gaps, and next steps. (2010) (32)
An accelerated pathway for targeted cancer therapies (2011) (32)
Principles for a Framework for Alternative Payment Models. (2018) (31)
A prescription for a modern Medicare program. (2005) (30)
Making the Case for Value-Based Payment Reform in Children's Health Care. (2018) (30)
Health Expenditure Persistence and the Feasibility of Medical Savings Accounts (1997) (29)
Trends in hospital treatment of ventricular arrhythmias among Medicare beneficiaries, 1985 to 1995. (2002) (28)
Building A Better Health Care System Post-Covid-19: Steps for Reducing Low-Value and Wasteful Care (2020) (27)
Moving Beyond the Walls of the Clinic: Opportunities and Challenges to the Future of Telehealth in Heart Failure. (2017) (27)
Measuring health care performance now, not tomorrow: essential steps to support effective health reform. (2011) (26)
Medicare reform: fundamental problems, incremental steps. (2000) (24)
Competencies and Tools to Shift Payments From Volume to Value. (2016) (23)
Advancing Value Assessment in the United States: A Multistakeholder Perspective. (2017) (23)
Aligning payment reform and delivery innovation in emergency care. (2016) (23)
Improving Care And Lowering Costs: Evidence And Lessons From A Global Analysis Of Accountable Care Reforms. (2017) (23)
Designing a Medicare prescription drug benefit: issues, obstacles, and opportunities. (2000) (23)
Existing and Emerging Payment and Delivery Reforms in Cardiology (2017) (23)
Coverage with evidence development for Medicare beneficiaries: challenges and next steps. (2013) (22)
Cardiac Procedure Use and Outcomes in Elderly Patients with Acute Myocardial Infarction in the United States and Quebec, Canada, 1988 to 1994 (2003) (22)
Advancing Value-Based Models for Heart Failure (2020) (22)
Medicare reform: who pays and who benefits? (1999) (22)
The costs of decedents in the Medicare program: implications for payments to Medicare + Choice plans. (2004) (22)
Shifting Away From Fee-For-Service: Alternative Approaches to Payment in Gastroenterology. (2016) (21)
A National COVID-19 Surveillance System: Achieving Containment (2020) (19)
Advance Directives and Medical Treatment at the End of Life (2003) (19)
Impact of Spinal Cord Stimulation on Opioid Dose Reduction: A Nationwide Analysis. (2020) (18)
Are the returns to technological change in health care declining? (1996) (18)
Managed Care, Health Care Quality, and Regulation (2001) (18)
Accountable care organizations and evidence-based payment reform. (2015) (18)
The 21st Century Cures Act. (2015) (17)
Value-based arrangements may be more prevalent than assumed. (2019) (17)
ACO Serious Illness Care: Survey And Case Studies Depict Current Challenges And Future Opportunities. (2019) (17)
Bending the curve through health reform implementation. (2010) (17)
Spending growth rates: are the differences real? (1999) (17)
Improving Health While Reducing Cost Growth : What is Possible ? (2014) (16)
Why Do Accountable Care Organizations Leave The Medicare Shared Savings Program? (2019) (15)
Commentary: Tackling the Challenges of Developing Targeted Therapies for Cancer (2010) (15)
Prices and Productivity in Managed Care Insurance (1998) (15)
Literature Review and Synthesis (2001) (15)
Medical Liability, Managed Care, and Defensive Medicine (2000) (14)
Understanding Use of Real‐World Data and Real‐World Evidence to Support Regulatory Decisions on Medical Product Effectiveness (2021) (14)
Payment Reform for Better Value and Medical Innovation (2017) (14)
Refinement of the HCUP Quality Indicators: Prepared for Agency for Healthcare Research and Quality (2001) (14)
Improving pharmaceutical innovation by building a more comprehensive database on drug development and use. (2015) (14)
Medicare Reimbursement and Hospital Cost Growth (1996) (14)
Designing Hospital Antitrust Policy to Promote Social Welfare (1999) (14)
Reducing uninsurance through the nongroup market: health insurance credits and purchasing groups. (2002) (14)
Biomedical Research and Then Some: The Causes of Technological Change in Heart Attack Treatment (2003) (14)
Addressing Antimicrobial Resistance and Stewardship: The Priority Antimicrobial Value and Entry (PAVE) Award. (2017) (13)
ACO Quality Over Time : The MSSP Experience and Opportunities for System-Wide Improvement (13)
International differences in patient and physician perceptions of "high quality" healthcare: a model from pediatric cardiology. (2006) (12)
What Is Technological Change (1998) (12)
Engaging Beneficiaries In Medicaid Programs That Incentivize Health-Promoting Behaviors. (2019) (11)
Current Policy and Practice for Value-Based Pricing. (2019) (11)
Payment Reform to Enhance Collaboration of Primary Care and Cardiology: A Review (2017) (11)
Streamlining and Reimagining Prior Authorization Under Value-Based Contracts: A Call to Action From the Value in Healthcare Initiative’s Prior Authorization Learning Collaborative (2020) (10)
Fully Capitated Payment Breakeven Rate for a Mid-Size Pediatric Practice (2016) (10)
Why a Proactive Perioperative Medicine Policy Is Crucial for a Sustainable Population Health Strategy. (2017) (10)
Realizing the Full Potential of Precision Medicine in Health and Health Care: A Vital Direction for Health and Health Care (2016) (10)
Trends in Heart Attack Treatment and Outcomes, 1975-1995 -- Literature Review and Synthesis (2001) (10)
Meaningful Physician Payment Reform in Oncology. (2013) (10)
Diagnosis and Medicare Expenditures at the End of Life (1998) (9)
A National Decision Point: Effective Testing and Screening for Covid-19 (2020) (9)
Case study: Transforming cancer care at a community oncology practice. (2015) (9)
Medicare physician payment reform: will 2014 be the fix for SGR? (2014) (9)
Accountable Care Reforms Improve Women's And Children's Health In Nepal. (2017) (9)
Toward Evidence-Based Policy Making to Reduce Wasteful Health Care Spending. (2019) (9)
Improving Cardiovascular Drug and Device Development and Evidence Through Patient-Centered Research and Clinical Trials (2020) (8)
Implementation Research to Address the United States Health Disadvantage: Report of a National Heart, Lung, and Blood Institute Workshop. (2018) (8)
Specialty Payment Model Opportunities and Design (2014) (8)
Fostering Accountable Health Care: Moving Forward In (2009) (8)
Bundled Payments Are Moving Upstream (2019) (8)
Transforming oncology care: payment and delivery reform for person-centered care. (2015) (8)
Innovations In Diabetes Care Around the World: Case Studies Of Care Transformation Through Accountable Care Reforms. (2015) (8)
Seven Former FDA Commissioners: The FDA Should Be An Independent Federal Agency. (2019) (8)
Value-Based Care in the COVID-19 Era: Enabling Health Care Response and Resilience (2020) (8)
Improving Oncology Quality Measurement in Accountable Care: Filling Gaps with Cross-Cutting Measures. (2017) (7)
Strategies For Assessing Delivery System Innovations. (2017) (7)
Understanding the Need for Non-Interventional Studies Using Secondary Data to Generate Real-World Evidence for Regulatory Decision Making, and Demonstrating Their Credibility (2019) (7)
Medicaid and CHIP Child Health Beneficiary Incentives: Program Landscape and Stakeholder Insights (2019) (7)
Better Evidence to Guide Payment Reforms: Recognizing the Importance of Perspective. (2017) (6)
COVID-19 Manufacturing for Monoclonal Antibodies (2020) (6)
More Value From Payment Reform in Health Care and Biomedical Innovation. (2016) (6)
Two Drugs for Opioid Dependence (2002) (6)
Where the Money Goes: Medical Expenditures in a Large Corporation (1995) (6)
A Roadmap for Value‐Based Payment Models Among Patients With Cirrhosis (2019) (6)
Vital Directions For Health And Health Care: Priorities For 2021. (2021) (6)
Improving patient-reported measures in oncology: a payer call to action. (2020) (6)
Building a drug development database: challenges in reliable data availability (2017) (5)
Sustainable Success in Accountable Care (2016) (5)
A Case Study in Payment Reform to Support Optimal Pediatric Asthma Care (2015) (5)
Frontiers of Upstream Stroke Prevention and Reduced Stroke Inequity Through Predicting, Preventing, and Managing Hypertension and Atrial Fibrillation (2020) (5)
Payment and Care for Hematopoietic Cell Transplantation Patients: Toward a Specialized Medical Home for Complex Care Patients. (2018) (5)
Health Care Payers COVID-19 Impact Assessment: Lessons Learned and Compelling Needs. (2021) (5)
Achieving the Goals of Effective, Safe, and Individualized Cancer Care (2011) (5)
Reforming Provider Payment Moving Toward Accountability for Quality and Value Statement of (2009) (4)
Pediatric accountable health communities: Insights on needed capabilities and potential solutions. (2020) (4)
Oncology payment reform to achieve real health care reform. (2015) (4)
Preclinical Alzheimer Disease Drug Development: Early Considerations Based on Phase 3 Clinical Trials. (2020) (4)
The uncertain demand for medical care a comment on Emmett Keeler (1995) (4)
MORTALITY AFTER ACUTE MYOCARDIAL INFARCTION IN HOSPITALS THAT DISPROPORTIONATELY TREAT AFRICAN-AMERICANS (2005) (4)
The Sources of Cost Difference in Health Insurance Plans: A Decomposition Analysis (1999) (4)
Remarks of the Commissioner of Food and Drugs. (2003) (4)
The economics of medical treatment intensity (1993) (4)
Trends in Medicare Spending Near the End of Life (2001) (3)
Community Based Approaches for Optimal Asthma Outcomes and Accountable Population Health (2015) (3)
Medicare Part D: opportunities and challenges for pharmacy. (2005) (3)
The Clinical Trials Transformation Initiative: Looking back, looking forward (2018) (3)
Payment Reform, Medication Use, and Costs: Can We Afford to Leave Out Drugs? (2019) (3)
The Affordable Care Act: What's Next? (2018) (3)
Implementation of a Market Entry Reward within the United States (2018) (3)
Paying For Value From Costly Medical Technologies: A Framework For Applying Value-Based Payment Reforms. (2020) (3)
Four important steps toward 21st century care for patients with cancer. (2009) (3)
Association of ACO Shared Savings Success and Serious Illness Spending (2021) (2)
Prospective or retrospective ACO attribution matters for seriously ill patients. (2020) (2)
Advancing Value-Based Cardiovascular Care (2020) (2)
Reforms Needed to Modernize the US Food and Drug Administration's Oversight of Dietary Supplements, Cosmetics, and Diagnostic Tests. (2022) (2)
Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in chronic heart failure [2] (multiple letters) (2005) (2)
Health Care Payment to Support COVID-19 Detection and Containment (2020) (2)
Estimating treatment effects with observational data : A new approach using hospital-level variation in treatment intensity (1999) (2)
New Drug for Hepatitis B (2002) (2)
Fixing the (Un)Sustainable Growth Rate Formula: Shifting From Volume to Value (2013) (1)
Use of outcomes research in assuring patient safety and quality care, second plenary session, ISPOR 8th annual international meeting, Arlington, VA, USA. (2004) (1)
Help your patients become aware of the new medicare prescription drug plans. (2005) (1)
Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Chronic Heart Failure (Letter) (2005) (1)
Medicare Part D prescription coverage: what it means for primary care physicians. (2005) (1)
Adjuvant Breast Cancer Treatment (2002) (1)
Breast Cancer: Treatment, Outcomes, and Cost-Effectiveness (1997) (1)
Request for Grant Applications (2002) (1)
Why Do Some Firms Spend So Much on Medical Care? Accounting for Variation (2000) (1)
Legislative and Regulatory Steps for a National COVID-19 Testing Strategy (2020) (1)
Fifth Annual David A. Winston Lecture. (2004) (1)
Competencies and Tools to Shift Payments from Volume to Value: A Vital Direction for Health and Health Care (2016) (1)
North Carolina's Health Care Transformation to Value (2020) (1)
Advancing Integrated Care in England : A Practical Path for Care Transformation (2018) (1)
FDA: protecting and advancing America's health. (2004) (1)
The Past Decade of Paying for Value : From the Affordable Care Act to COVID-19 (2020) (1)
Inconsistent Reporting of Potential Conflicts of Interest in JAMA Pediatrics. (2019) (1)
Betting on Better Drug Trials to Beat Covid-19 (2020) (1)
New FDA breakthrough-drug category--implications for patients. (2014) (1)
Engaging Patients in Value-Based Cancer Care: A Missed Opportunity (2018) (1)
Inconsistent Reporting of Potential Conflicts of Interest in JAMA. (2018) (1)
Refinement of the HCUP Quality Indicators: Contents and Text of Report (2001) (1)
Inconsistent Reporting of Potential Conflicts of Interest in JAMA Cardiology. (2019) (1)
Solutions for filling gaps in accountable care measure sets. (2015) (1)
43. Opportunities and limitations in role development for technologists (1996) (1)
Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in chronic heart failure. (2005) (1)
Solutions for filling gaps in accountable care measure sets. (2015) (1)
Response to comments on ‘Comparative Effectiveness Research’ (2010) (1)
IMPROVING PROVIDER PROFILES FOR ASSESSING QUALITY OF CARE IN A HIGH RISK PATIENT POPULATION (2002) (1)
The Evolving Payment Reform Landscape: New Opportunities for Gastroenterology Leadership (2017) (1)
2004 SCHROEDER SCHOLAR IN RESIDENCE LECTURE -- FDA: Protecting and Advancing America's Health (2004) (0)
Mission: promoting, protecting the public health. FDA Commissioner Mark B. McClellan. Interview by Ray Formanek Jr. (2003) (0)
Challenges to Reducing Low-Value Care: Lessons Learned and Future Directions (2018) (0)
Refinement of the HCUP Quality Indicators: List of figures and tables (2001) (0)
[Table, 3.E.5. In-Hospital Mortality Measures]. (2001) (0)
Empirical Evaluation Results Tables (2001) (0)
[Table], Table 4. List of HCUP I indicators, and inclusion status in HCUP II (2001) (0)
New Treatment for Hepatitis C (2002) (0)
[Table], Table 23. Summary of Factor Analysis Results, Provider-level indicatorsa (2001) (0)
[Table, 3.E.6. Post-Procedural Mortality Measures]. (2001) (0)
Think globally, protect locally: a conversation with Mark McClellan. (2004) (0)
Mark McClellan (2009) (0)
Medicare's new drug discount card. (2004) (0)
[Table], Table 24. Summary of Factor Analysis Results, Area-level ACSC indicatorsa (2001) (0)
[Table], Healthcare Cost and Utilization Project Quality Indicator Literature Review - Table of Clinical Domains (2001) (0)
Racial and gender differences in refusal of coronary angiography (2002) (0)
National Provider Identifier Activities Begin in 2005 (2005) (0)
Achieving value-driven health care. (2007) (0)
[Table], Table 25. Summary of Factor Analysis Results, Area-level utilization indicators (2001) (0)
Health leaders: Let’s #OpenSafely (2020) (0)
[Table, Empirical Evidence]. (2001) (0)
Mark McClellan, MD, PhD addressing the quality challenge. (2008) (0)
The Relationship Between Health Policies, Medical Technology Trends and Outcomes (2003) (0)
The 21st Annual Dr. Raymond C. Grandon Lecture: Health Reform, Two Years On (2012) (0)
Data Collection Instruments (2001) (0)
AMR: Antibiotics stewardship and innovation (2014) (0)
Overcoming Barriers to Biosimilar Adoption: Commentary on “Cost to Medicare of Delayed Adalimumab Biosimilar Availability” (2021) (0)
[Table], Table 6A. Studies of ACSC Indicators- Late Hospitalization (2001) (0)
Value Based Payment Shift for Independent Urology Practices: Roadmap and Barriers. (2022) (0)
Immediate Past Chairman of the Board (2010) (0)
[Table, Appendix 6 Indicator Definitions - Potential HCUP Indicators]. (2001) (0)
[Table], Table 2. Bias Tests (2001) (0)
Health Policy Priorities for the Biden Administration (2021) (0)
[Table, 3.E.4. Ambulatory Care Sensitive Condition Measures]. (2001) (0)
Is Netflix the Answer? Operationalizing the Subscription Model for Hepatitis C Therapies (2019) (0)
Keynote address: By Mark B. McClellan, M.D., Ph.D., Commissioner of Food and Drugs, for Health Services and Outcomes Research Conference, Houston, Texas, November 25, 2002: (310752004-001) (2002) (0)
[Table], Table 8. Example clinical groupings (2001) (0)
[Table], Table 3. Construct Validity Tests (2001) (0)
Refinement of the HCUP Quality Indicators: Appendix 1 Peer Reviewers (2001) (0)
Covid Shows the Need for a Diagnostic Stockpile (2020) (0)
Association of medical school training and quality of myocardial infarction care (2002) (0)
Can Innovation in Regulatory Science Address Health Care Cost Burdens? (2019) (0)
[Table], Table 22. Minimum Bias - Area Indicatorsa,b (2001) (0)
Medicare and the Federal Budget: Past Experience, Current Policy, Future Prospects (2001) (0)
ImpactofHealthInsuranceonHealthCareTreatmentandCostin Vietnam:AHealthCapabilityApproachtoFinancialProtection (2012) (0)
[Table], Table 10. Summary evidence table for provider level utilization indicators (2001) (0)
Competitive Implications of Health Plan Pricing Rules in Medicare Reform Proposals Testimony before the Senate Committee on Finance Len Nichols (2015) (0)
Achieving Widespread Availability of Timely and Efficient COVID-19 Testing (2020) (0)
Moving physicians from fee-for-service first step to 'doc fix,' mcClellan says. (2014) (0)
Literature Tables for Utilization and ACSC Indicators (2001) (0)
[Figure], Figure 1. Abbreviated diagram of literature review. (2001) (0)
Inventory of Indicators (2001) (0)
[Table], Table 27. Risk adjustment statistics from the literature (2001) (0)
Opportunities for Private-Sector Entrepreneurship in Health CareTransformation (2017) (0)
[Table], Table 20. Precision - Area Indicatorsa,b (2001) (0)
Implementation through collaboration: The Brookings-Dartmouth ACO Learning Network. (2012) (0)
and Effective Medical Devices," New England Journal of Medi-cine 348, no. 3 (16 January 2003): 191" (2000) (0)
[Table], Table 5. List of other indicators, tested but not recommended due to low precision (2001) (0)
The Missing Piece in Value-Based Payment Reform: Consumer Engagement (2019) (0)
Novel State Payment Models for Prescription Drugs: Early Implementation Successes and Challenges (2019) (0)
Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in chronic heart failure. Authors' reply (2005) (0)
[Table], Table 16. Percentage of procedures and volume (2001) (0)
[Table], Table 13. Summary evidence table for mortality indicators (2001) (0)
Late Breaking: What Next for Drug Pricing? Policy Approaches to Promoting Value-based Care (2017) (0)
Refinement of the Affordable Care Act (2017) (0)
Contact List for Phone Interviews (2001) (0)
Assessing and Accelerating State Implementation of Value-Based Payment Reforms (2019) (0)
[Table], Table 19. Precision - Provider Indicatorsa,b (2001) (0)
Health Affairs Repairing The Broken Market For Antibiotic Innovation (2015) (0)
Money no excuse for hampering progress. Interview by Rebecca Allmark. (2007) (0)
[Table], Table 14. Thresholds for indicators (2001) (0)
[Table], Table 1S. Provider indicator list (2001) (0)
[Figure], Figure 2. Example search strings (2001) (0)
Testimony on Medicare Advantage and the Federal Budget Submitted (2007) (0)
Is the Time Right for a Permanent Fix to Medicare’s Formula for Physician Payment? (2013) (0)
HEALTHY PEOPLE 2010 FOCUS AREA PROGRESS REVIEW MEDICAL PRODUCT SAFETY (2010) (0)
The challenge of implementing the new Medicare drug benefit while updating physicians' pay. (2005) (0)
[Table], Table 17. Year to year persistence of high volume status (2001) (0)
From the Food and Drug Administration. (2002) (0)
Proposed Change of Patent Rules (2002) (0)
[Table], Table 5A. Studies of ACSC Indicators-Discretionary Hospitalization of Infants (2001) (0)
[Table], Table 2A. Studies of ACSC indicators (2001) (0)
[Table, List of acronyms and meanings used in the evidence report]. (2001) (0)
[Table, Empirical Evaluation Results Tables]. (2001) (0)
[Table], Table 21. Minimum Bias - Provider Indicatorsa,b (2001) (0)
Correction to: Comparing Associations of State Reopening Strategies with COVID-19 Burden (2020) (0)
Refinement of the HCUP Quality Indicators: Structured Abstract (2001) (0)
Interview with Mark McClellan, MD, PhD. (2004) (0)
Special Plenary: A Fireside Chat with Scott Gottlieb and Mark McClellan (2019) (0)
[Table], Table 4A. Studies of ACSC Indicators- Pediatric Avoidable Hospitalizations (2001) (0)
[Table], Table 2S. Area indicator list (2001) (0)
Medicare Drug Benefit: A Beneficial Side Effect of the Medicare Drug Benefit (2005) (0)
Refinement of the HCUP Quality Indicators: Appendix 8A Literature Tables for Utilization and ACSC Indicators (2001) (0)
[Table], Table 9. Summary evidence table for volume indicators (2001) (0)
[Table], Table 1A. Studies of appropriateness of specific procedures (2001) (0)
Refinement of the HCUP Quality Indicators: Appendix 5 Inventory of Indicators (2001) (0)
[Table, 3.E.3. Area-level utilization measures]. (2001) (0)
RW3 UNDERSTANDING USE OF REAL-WORLD DATA (RWD) AND REAL-WORLD EVIDENCE (RWE) TO SUPPORT EFFECTIVENESS LABELING CHANGES (2020) (0)
Triggering the Tipping Point in Payment Reform (2017) (0)
[Table], Table 26. Summary of Telephone Contacts August 1999 through March 2001 (2001) (0)
[Table], Table 15. Volume distribution by year (2001) (0)
Refinement of the HCUP Quality Indicators: Appendix 6 Indicator Definitions (2001) (0)
List of Abstracted Articles (2001) (0)
[Table], Table 12. Summary evidence table for area-level ACSC indicators (2001) (0)
Refinement of the HCUP Quality Indicators: Appendix 9 List of Acronyms (2001) (0)
CMS Alliance to Modernize Healthcare (2014) (0)
You Can Trust the FDA’s Vaccine Process (2020) (0)
OWNERSHIP FORM AND CAPACITY CHOICE IN THE HOSPITAL INDUSTRY (2002) (0)
Refinement of the HCUP Quality Indicators: Appendix 7 Empirical Evaluation Results Tables (2001) (0)
THE CE NTER FOR FOOD AFETY April (2003) (0)
[Figure], Figure 1S. Flow chart of the identification of recommended indicators (2001) (0)
[Table, 3.E.1 Volume Measures]. (2001) (0)
Individual Expenditures and Medical Saving Accounts (2003) (0)
[Table, Data Collection Instruments]. (2001) (0)
Steering committee (2004) (0)
Wachter, McClellan offer takes on measuring quality. (2014) (0)
A Comparison of the Quality of Health Care in the United States and Japan (2006) (0)
[Table], Table 11. Summary evidence table for area-level utilization indicators (2001) (0)
Mark McClellan (2012) (0)
Hospital‐level compliance with the commission on cancer’s quality of care measures and the association with patient survival (2021) (0)
Accelerating the Transformation of Healthcare (2020) (0)
[Table, 3.E.2 Provider-Level Utilization Measures]. (2001) (0)
[Table], Table 1. Precision Tests (2001) (0)
Refinement of the HCUP Quality Indicators: Appendix 3 List of Abstracted Articles (2001) (0)
Individual Expenditures and Medical Saving Accounts: Can They Work? (2003) (0)
Go To U.S. District Court Opinion View Original Source Image of This Document (2003) (0)
Unique Device Identification (UDI) Implementation Expert Workshop: Identifying Steps for Implementation and Integration of UDI within Electronic Data Infrastructure of Care Delivery Sites (2012) (0)
Testimony of Mark B. McClellan, MD, Ph.D (2005) (0)
Medicare Part D Prescription Coverage (2005) (0)
Re: Request for Comment Period Extension on Draft Decision Memorandum for Anticancer Chemotherapy for Colorectal Cancer (CAG-00179N) (2004) (0)
Racial differences in endocarditis treatment and outcome (2002) (0)
An accelerated pathway for targeted cancer therapies A well-defined pathway for the accelerated development and approval of targeted cancer therapies and companion diagnostics would reduce uncertainty, improve efficiency in development and provide an effective incentive for developers. (2011) (0)
From Development to Market: Understanding COVID-19 Testing and Its Challenges (2020) (0)
Advancing Treatments to Save Lives and Reduce the Risk of COVID-19 (2020) (0)
and Health-Care Choices (2017) (0)
FROM THE EDITOR The Nutraceutical Journey: From Laboratory Technique to Marketing Communications (2008) (0)
[Table], Table 18. Correlations between volume and mortality indicatorsa (2001) (0)
[Table, Inventory of Indicators]. (2001) (0)
Refinement of the HCUP Quality Indicators: Appendix 8B (2001) (0)
Conclusions and Future Research (2001) (0)
Primary care physician-led health reform--reply. (2014) (0)

This paper list is powered by the following services:

Mark B. Mcclellan's Academic­Influence.com Rankings

Mark B. Mcclellan's Degrees

Why Is Mark B. Mcclellan Influential?

Mark B. Mcclellan's Published Works

Published Works

Mark B. Mcclellan's AcademicInfluence.com Rankings